IDEAYA Biosciences, Inc. (IDYA) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
IDYA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
IDYA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 97.9% | -72.8% | -52.0% |
| 2024 | 45.2% | -4671.1% | -3921.1% |
| 2023 | 82.9% | -574.9% | -483.0% |
| 2022 | 95.9% | -122.7% | -115.2% |
| 2021 | 93.8% | -179.9% | -178.1% |
Download Data
Export IDYA earnings history in CSV or JSON format
Free sign-in required to download data
IDEAYA Biosciences, Inc. (IDYA) Earnings Overview
As of May 8, 2026, IDEAYA Biosciences, Inc. (IDYA) reported trailing twelve-month net income of -$140M, reflecting +61.9% year-over-year growth. The company earned $-1.58 per diluted share over the past four quarters, with a net profit margin of -52.0%.
Looking at the long-term picture, IDYA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$12M in fiscal 2017.
IDEAYA Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including TPVG (-$12M net income, 50.6% margin), AGEN ($115,000 net income, 0.1% margin), IMVT (-$464M net income), IDYA has room to improve margins relative to the peer group. Compare IDYA vs TPVG →
IDYA Earnings vs Peers
Earnings metrics vs comparable public companies
IDYA Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$114M | +58.6% | -$159M | $-1.28 | -52.0% | -72.8% |
| 2024 | -$274M | -143.0% | -$327M | $-3.36 | -3921.1% | -4671.1% |
| 2023 | -$113M | -92.6% | -$134M | $-1.96 | -483.0% | -574.9% |
| 2022 | -$59M | -17.9% | -$63M | $-1.42 | -115.2% | -122.7% |
| 2021 | -$50M | -44.3% | -$50M | $-1.41 | -178.1% | -179.9% |
| 2020 | -$34M | +17.8% | -$35M | $-1.31 | -176.6% | -180.9% |
| 2019 | -$42M | -22.2% | -$44M | $-1.90 | - | - |
| 2018 | -$34M | -189.5% | -$36M | $-2.41 | - | - |
| 2017 | -$12M | - | -$14M | $-0.83 | - | - |
See IDYA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IDYA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IDYA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIDYA — Frequently Asked Questions
Quick answers to the most common questions about buying IDYA stock.
Is IDYA growing earnings?
IDYA EPS is $-1.58, with earnings growth accelerating to +61.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-140M.
What are IDYA's profit margins?
IDEAYA Biosciences, Inc. net margin is -52.0%, with operating margin at -72.8%. Below-average margins reflect competitive or cost pressures.
How consistent are IDYA's earnings?
IDYA earnings data spans 2017-2025. The accelerating earnings trend is +61.9% YoY. Historical data enables comparison across business cycles.